… This phase III study evaluated overall survival (OS) and other safety and efficacy end points
… with advanced melanoma treated with tremelimumab or standard-of-care chemotherapy. …

… On the basis of these observations, we conducted a randomized phase II trial to evaluate
these two strategies in the first-line management of advanced NSCLC patients with PS 2. We …

… patients had been treated in randomized phase III trials. … high-dose chemotherapy after
standard chemotherapy does not … randomized studies that incorporated bone marrow ablative …

… , randomized multicenter phase II clinical trial to assess the efficacy and safety of BV added
to first-line standard chemotherapy (… patients receiving BV and chemotherapy, compared with …

… , randomized phase III Korean trial if they had histologically confirmed AGC and had not seen
benefit after one or two chemotherapy … platinum-based chemotherapy or a fluoropyrimidine …

… Patients were randomized in a 1 : 1 allocation to receive standard-dose or dose-intensified
preoperative chemotherapy. Patients within each treatment arm were further randomized in a …

… This randomized, open-label, phase III clinical trial compared the efficacy between
standard CCRT and two different induction chemotherapy (ICT) regimens followed by CCRT. …

… : Chemotherapy (CT) is the standard of … randomized multicenter phase III trial resectability
was judged by an independent surgical board. Patients (pts) received induction chemotherapy …

… Arm A reached the primary end point with an estimated MST longer than 18 months and
will be compared with a standard dose of TRT in a planned randomized phase III trial in the …

… II trial of circadian timed (CT) doxorubicin plus cisplatin chemotherapy in advanced or …
patients receiving CT chemotherapy, this randomized phase III trial comparing standard timed (ST) …